New immuno-active principles for optimizing Echinacea

优化紫锥菊的新免疫活性原理

• 批准号: 6522226
• 负责人: DAVID S PASCO
• 金额: $ 17.94万
• 依托单位: UNIVERSITY OF MISSISSIPPI
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-07-15 至 2004-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6522226
• 关键词: alternative medicine; biomaterial development /preparation; drug screening /evaluation; gene expression; glycosides; high performance liquid chromatography; human tissue; inulin; leukocyte activation /transformation; luciferin monooxygenase; messenger RNA; monocyte; nuclear factor kappa beta; pharmacokinetics; plant extracts; polymerase chain reaction; reporter genes; resin; sesquiterpenes; solvents; species difference; thin layer chromatography

DESCRIPTION (provided by applicant): Echinacea species represent the most widely used botanical in the United States herbal market. These products vary considerably with respect to the species used, the plant part, and the formulation. Since these different products can have distinctly different chemistries, it would be expected that they would exhibit different pharmacological effects. This level of complexity most likely contributes to the problem of interpreting clinical trials performed to date on these different preparations. It also underscores the importance of identifying the clinically relevant compounds within the different preparations so that standardized consistent products could be produced for the consumer market and for use in clinical trials.Strong preliminary evidence is presented that unknown compounds, extractable with organic solvents, exist within Echinacea species that are potent activators, enhancers and suppressors of monocyte function. Determining the relevance of these compounds to the therapeutic efficacy of Echinacea material will ultimately lead to the development of optimized and more appropriately standardized products. In the longterm, this research could more directly influence human health by providing information on the types of Echinacea products most appropriate for specific health concerns. These compounds will be characterized, and their relevance to the pharmacological activity of Echinacea determined, as follows: 1. A human monocyte test system, employing a luciferase reporter gene driven by NF-kappa B sequences, will be used to guide the characterization of the compounds responsible for these three activities. 2. Cloned E. angustifolia plants (propagated in vitro) will be selected for predominant expression of only one of these activities. This will facilitate isolation since they represent a consistent and unlimited source of material. 3. Determine whether the extract's ability to modify monocyte activation correlates with the levels of these newly characterized compounds within the various plant parts of E. angustifolia, E. purpurea, and E. pallida.

描述（由申请人提供）：紫锥菊属物种代表了美国草药市场上最广泛使用的植物。这些产品在使用的物种、植物部分和配方方面差异很大。由于这些不同的产品可能具有明显不同的化学性质，因此预计它们将表现出不同的药理学作用。这种复杂程度很可能导致解释迄今为止对这些不同制剂进行的临床试验的问题。它还强调了在不同的制剂中识别临床相关化合物的重要性，以便可以为消费者市场和临床试验中使用的标准化一致的产品，提出了强有力的初步证据，即未知化合物，用有机溶剂提取，存在于紫锥菊属物种是有效的激活剂，单核细胞功能的增强剂和抑制剂。确定这些化合物与紫锥菊材料的治疗功效的相关性将最终导致优化和更适当标准化产品的开发。从长远来看，这项研究可以通过提供最适合特定健康问题的紫锥菊产品类型的信息，更直接地影响人类健康。这些化合物将被表征，并且它们与紫锥菊的药理活性的相关性被确定如下：1.采用NF-κ B序列驱动的荧光素酶报告基因的人单核细胞试验系统将用于指导负责这三种活性的化合物的表征。2.克隆E.选择仅主要表达这些活性之一的沙枣植物（体外繁殖）。这将有助于隔离，因为它们代表了一致和无限的材料来源。3.确定是否提取物的能力，修改单核细胞活化与这些新的特点化合物的水平在不同的植物部分E。angustifolia、狭叶E. purpurea和E.苍白球